FDA Grants Breakthrough Device Designation for Roche Alzheimer’s Early-Detection Solution
The FDA granted Roche Breakthrough Device Designation for its Elecsys Amyloid Plasma Panel, designed to enable earlier Alzheimer’s detection.
Read MorePosted by Andy Lundin | Aug 2, 2022 | Dementias & Alzheimer’s |
The FDA granted Roche Breakthrough Device Designation for its Elecsys Amyloid Plasma Panel, designed to enable earlier Alzheimer’s detection.
Read MorePosted by Andy Lundin | Jul 26, 2022 | Diagnostic Technologies, Disease States |
A new test may make it easier for newborns to get care for spinal muscular atrophy, a genetic disease that is life-threatening but treatable.
Read MorePosted by Andy Lundin | Jul 19, 2022 | Company News |
Natera, a global provider in cfDNA testing, has been selected to participate in UnitedHealthcare’s Preferred Laboratory Network.
Read MorePosted by Chris Wolski | Jul 12, 2022 | Emerging & Zoonotic Diseases, Molecular Diagnostics |
Co-Diagnostics, Inc. has shipped testing reagents for monkeypox virus currently exhibiting a multi-country outbreak.
Read MorePosted by Chris Wolski | Jul 12, 2022 | Molecular Diagnostics |
A new study found that pharmacogenomic genetic testing can help providers avoid prescribing antidepressant medications.
Read More